Compounds from diverse natural origin against triple-negative breast cancer: A comprehensive review
- PMID: 36323650
- DOI: 10.1111/cbdd.14172
Compounds from diverse natural origin against triple-negative breast cancer: A comprehensive review
Abstract
Triple-negative breast cancer (TNBC) is caused due to the lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor 2 (HER2) expression. Triple-negative breast cancer is the most aggressive heterogeneous disease that is capable of producing different clones and mutations. Tumorigenesis in TNBC is caused due to the mutation or overexpression of tumor suppressor genes. It is also associated with mutations in the BRCA gene which is linked to hereditary breast cancer. In addition, PARP proteins and checkpoint proteins also play a crucial function in causing TNBC. Many cell signaling pathways are dysregulated in TNBC. Even though chemotherapy and immunotherapy are good options for TNBC treatment, the response rates are still low in general. Many phytochemicals that are derived from natural compounds have shown very good inhibitions for TNBC. Natural compounds have the great advantage of being less toxic, having lesser side effects, and being easily available. The secondary metabolites such as alkaloids, terpenoids, steroids, and flavonoids in natural products make them promising inhibitors of TNBC. Their compositions also offer vital insights into inhibitory action, which could lead to new cancer-fighting strategies. This review can help in understanding how naturally occurring substances and medicinal herbs decrease specific tumors and pave the way for the development of novel and extremely efficient antitumor therapies.
© 2022 John Wiley & Sons Ltd.
Similar articles
-
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.Am Soc Clin Oncol Educ Book. 2016;35:34-42. doi: 10.1200/EDBK_159135. Am Soc Clin Oncol Educ Book. 2016. PMID: 27249684 Review.
-
Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype.BMC Cancer. 2013 Sep 3;13:403. doi: 10.1186/1471-2407-13-403. BMC Cancer. 2013. PMID: 24004841 Free PMC article.
-
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer.Clin Breast Cancer. 2021 Oct;21(5):383-390. doi: 10.1016/j.clbc.2020.12.011. Epub 2020 Dec 29. Clin Breast Cancer. 2021. PMID: 33781662 Review.
-
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.Breast Cancer Res Treat. 2018 May;169(1):175-187. doi: 10.1007/s10549-017-4646-1. Epub 2018 Jan 24. Breast Cancer Res Treat. 2018. PMID: 29368311 Free PMC article.
-
Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action.Int J Mol Sci. 2024 Jun 6;25(11):6285. doi: 10.3390/ijms25116285. Int J Mol Sci. 2024. PMID: 38892472 Free PMC article. Review.
Cited by
-
A comparative study of healthy lifestyle behaviors and related factors among Iranian male and female adolescents: a cross-sectional study.BMC Public Health. 2025 Feb 11;25(1):558. doi: 10.1186/s12889-025-21688-6. BMC Public Health. 2025. PMID: 39934715 Free PMC article.
-
Cytotoxic Effects of Plant Secondary Metabolites and Naturally Occurring Bioactive Peptides on Breast Cancer Model Systems: Molecular Mechanisms.Molecules. 2024 Nov 7;29(22):5275. doi: 10.3390/molecules29225275. Molecules. 2024. PMID: 39598664 Free PMC article. Review.
-
The Use of Schisandrin B to Combat Triple-Negative Breast Cancers by Inhibiting NLRP3-Induced Interleukin-1β Production.Biomolecules. 2024 Jan 5;14(1):74. doi: 10.3390/biom14010074. Biomolecules. 2024. PMID: 38254674 Free PMC article.
-
Recent biological applications of heterocyclic hybrids containing s-triazine scaffold.RSC Adv. 2023 Oct 17;13(43):30462-30490. doi: 10.1039/d3ra05953g. eCollection 2023 Oct 11. RSC Adv. 2023. PMID: 37854486 Free PMC article. Review.
-
The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer.Front Pharmacol. 2024 Mar 4;15:1349242. doi: 10.3389/fphar.2024.1349242. eCollection 2024. Front Pharmacol. 2024. PMID: 38500769 Free PMC article. Review.
References
REFERENCES
-
- Aimaiti, S., Suzuki, A., Saito, Y., Fukuyoshi, S., Goto, M., Miyake, K., Newman, D. J., O'Keefe, B. R., Lee, K. H., & Nakagawa-Goto, K. (2018). Corymbulosins I-W, cytotoxic clerodane diterpenes from the bark of Laetia corymbulosa. Journal of Organic Chemistry, 83(2), 951-963. https://doi.org/10.1021/acs.joc.7b02951
-
- AlGhalban, F. M., Khan, A. A., & Khattak, M. N. K. (2021). Comparative anticancer activities of Ficus carica and Ficus salicifolia latex in MDA-MB-231 cells. Saudi Journal of Biological Sciences, 28(6), 3225-3234. https://doi.org/10.1016/j.sjbs.2021.02.061
-
- Alsamri, H., El Hasasna, H., Al Dhaheri, Y., Eid, A. H., Attoub, S., & Iratni, R. (2019). Carnosol, a natural polyphenol, inhibits migration, metastasis, and tumor growth of breast cancer via a ROS-dependent proteasome degradation of STAT3. Frontiers in Oncology, 9, 1-11. https://doi.org/10.3389/fonc.2019.00743
-
- Alshaeri, H. K., Alasmari, M. M., Natto, Z. S., & Pino-Figueroa, A. (2020). Effects of annona muricata extract on triple-negative breast cancer cells mediated through EGFR signaling. Cancer Management and Research, 12, 12519-15226. https://doi.org/10.2147/CMAR.S278647
-
- Anders, C. K., Abramson, V., Tan, T., & Dent, R. (2016). The evolution of triple-negative breast cancer: From biology to novel therapeutics. American Society of Clinical Oncology Educational Book, 35, 34-42. https://doi.org/10.1200/EDBK_159135
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous